Encellin

About Encellin

Encellin is dedicated to advancing next-generation therapies, focusing initially on endocrine disorders. Their mission is to empower living medicines by leveraging the power of cells as smart molecular factories to deliver sophisticated therapies through minimally invasive implants.

Products & Services

Encapsulated Cell Replacement Therapy (ENCRT):A minimally invasive implant that helps cells survive in the body, functioning as smart molecular factories to release therapeutics as needed, targeting chronic diseases starting with endocrine disorders.

Specialties

Cell Encapsulation Technology Endocrine Disorder Therapies Type 1 Diabetes Treatment Minimally Invasive Implants

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 9900000 MR: - FA: $9.9M FAN: 9900000	D: 2023-12-13 FD: 2023-12-13	2 investors

Seed Latest

2023-12-13

$9.9M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tejal Desai

Professor and Chair of Bioengineering and Therapeutic Sciences at UCSF

C

Crystal Nyitray

CEO, Founder, Inventor

G

Grace Wei

COO, Founder

R

Ronald Martell

Strategic Advisor, Founder and CEO of Jasper Therapeutics

G

Greg Szot

Preclinical Advisor, Director of Islet Transplant Facility

V

Vern Norviel

Intellectual Property Partner at WSGR

View 4 more team members with Pro

Unlock Full Team Directory

Recent News

Encellin Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised